Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression.

Authors :: Schaff LR
Marghoob A
Rosenblum MK
Meyer R
Khakoo Y
Source :: Pediatric dermatology [Pediatr Dermatol] 2019 Jul; Vol. 36 (4), pp. 497-500. Date of Electronic Publication: 2019 Mar 13.
Publication Year :: 2019
Abstract: Neurocutaneous melanosis (NCM) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16-year-old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNFα inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti-TNF therapy for inflammatory bowel disease.<br /> (© 2019 Wiley Periodicals, Inc.)

Subjects :: Adalimumab therapeutic use
Adolescent
Follow-Up Studies
Humans
Immunosuppressive Agents adverse effects
Immunosuppressive Agents therapeutic use
Inflammatory Bowel Diseases drug therapy
Inflammatory Bowel Diseases pathology
Magnetic Resonance Imaging methods
Male
Melanosis diagnosis
Melanosis therapy
Meningeal Neoplasms diagnostic imaging
Neurocutaneous Syndromes diagnosis
Neurocutaneous Syndromes therapy
Nevus, Pigmented diagnosis
Nevus, Pigmented pathology
Nevus, Pigmented surgery
Rare Diseases
Risk Assessment
Skin Neoplasms diagnosis
Skin Neoplasms therapy
Tomography, X-Ray Computed methods
Treatment Outcome
Adalimumab adverse effects
Cell Transformation, Neoplastic pathology
Melanosis pathology
Meningeal Neoplasms secondary
Meningeal Neoplasms surgery
Neurocutaneous Syndromes pathology
Skin Neoplasms pathology

Full Text Access

Tools